RP1's IGNYTE study efficacy results were deemed evaluable and clinically meaningful by the FDA's Cell, Tissue, and Gene Therapies Advisory Committee. The favorable outcome is a key regulatory milestone as the company awaits an August 2 action date.
RP1's IGNYTE study efficacy results were deemed evaluable and clinically meaningful by the FDA's Cell, Tissue, and Gene Therapies Advisory Committee. The favorable outcome is a key regulatory milestone as the company awaits an August 2 action date.